The price of Asensus Surgical Inc. (AMEX:ASXC) shares last traded on Wall Street rose 1.87% to $0.31.
Based on available information, 2 analysts follow Asensus Surgical Inc. (AMEX:ASXC). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $2.00 and a low of $1.30, we find $1.65. Given the previous closing price of $0.30, this indicates a potential upside of 450.0 percent. ASXC stock price is now -41.80% away from the 50-day moving average and -45.27% away from the 200-day moving average. The market capitalization of the company currently stands at $71.71M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
Among analysts, 0 rate the stock a hold while 2 rate it a buy. Brokers who have rated the stock have averaged $1.65 as their price target over the next twelve months.
With the price target of $1.50, Cantor Fitzgerald recently initiated with Overweight rating for Asensus Surgical Inc. (AMEX: ASXC).
In other news, Biffi Andrea, Director bought 293,077 shares of the company’s stock on Mar 03. The stock was bought for $207,557 at an average price of $0.71. Upon completion of the transaction, the Director now directly owns 492,815 shares in the company, valued at $0.15 million. Insiders disposed of 652,699 shares of company stock worth roughly $0.2 million over the past 1 year. A total of 0.10% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in ASXC stock. A new stake in Asensus Surgical Inc. shares was purchased by MASTERS CAPITAL MANAGEMENT LLC during the first quarter worth $564,000. ALPHACENTRIC ADVISORS LLC invested $153,000 in shares of ASXC during the first quarter. In the first quarter, LAZARI CAPITAL MANAGEMENT, INC. acquired a new stake in Asensus Surgical Inc. valued at approximately $21,000. TWO SIGMA INVESTMENTS, LP acquired a new stake in ASXC for approximately $20,000. JPMORGAN CHASE & CO purchased a new stake in ASXC valued at around $14,000 in the second quarter. In total, there are 91 active investors with 12.20% ownership of the company’s stock.
A candlestick chart of Asensus Surgical Inc. (AMEX: ASXC) showed a price of $0.3400 on Friday morning. During the past 12 months, Asensus Surgical Inc. has had a low of $0.28 and a high of $1.18. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 6.60, and a quick ratio of 5.80. The fifty day moving average price for ASXC is $0.5202 and a two-hundred day moving average price translates $0.5583 for the stock.
The latest earnings results from Asensus Surgical Inc. (AMEX: ASXC) was released for Mar, 2023. According to the Medical Devices Company, earnings per share came in at -$0.09, missing analysts’ expectations of -$0.08 by -0.01. This compares to -$0.08 EPS in the same period last year. The company reported revenue of $0.98 million for the quarter, compared to $1.07 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -8.44 percent. For the current quarter, analysts expect ASXC to generate $1.07M in revenue.
Asensus Surgical Inc.(ASXC) Company Profile
Asensus Surgical, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery (MIS) in the United States, Europe, the Middle East, Africa, and Asia. It digitizes the interface between the surgeon and the patient to pioneer a new era of Performance-Guided surgery by unlocking clinical intelligence for surgeons to enable consistently superior outcomes and a new standard of surgery. The company’s products include Senhance Surgical system, a multi-port robotic surgery system that allows up to four arms to control robotic instruments and a camera for laparoscopic procedures. Its products also comprise instruments and other products, including 3mm diameter instruments, 3mm and 5mm hooks, and articulating instruments; and Senhance ultrasonic system, an advanced energy device to deliver controlled energy to ligate and divide tissue. The company was formerly known as TransEnterix, Inc. and changed its name to Asensus Surgical, Inc. in February 2021. Asensus Surgical, Inc. was founded in 2006 and is headquartered in Durham, North Carolina.
